Dr Khanna presents RECIPE RCT of MMF to reduce immunogenicity of pegloticase. Sustained urate response ≤6mg/dL at 24 weeks 68% with MMF compared to 30% in placebo. @rheumnow #ACR20 Abstr#952 #ACRbest https://t.co/64nN5AqK3W

Dr Merriman presents on role of diet in gout. It is minor, especially compared to urate lowering therapy. Average attributable fraction approximately 10-fold greater for ULT than following healthy-eating guidelines. @rheumnow #ACR20 Abstr#951 https://t.co/1tftswOEJq

Dr Cai presents risk of CVD in gout in study 450,000 patients. Gout was independently associated with an increased risk of CVD events HR = 1.24 for women; 1.21 for men. @rheumnow #ACR20 Abstr#950 #ACRbest https://t.co/089aKtN5a7

Evidence-Based Guidance for Optimizing Gout #ACR20 Reminding us of cardioprotective effect of anti-inflammatory gout management with colchicine. https://t.co/TmsrRd2vFD

Is diet important in gout control? #ACR20 @rheumnow

@RheumNow #acr20 abs0665 claim based database stdy of pegloticase/immunomodulation coadministration trends: use of co-immunomodulation ⬆️ from 1.2%-3.9% 2015- 2018 to 15.0% in 2019. 86%start immunomodulator within 30 days of first peg infusion. MTX most commonly used

@RheumNow #acr20 abs0690 ph2a trial: potent reduction of sUA w/URAT1 inhibitor AA882. 100% of pts sUA levels < 6 mg/dL &63% pts < 5 mg/dL compared to febuxostat 50% & 13% respectively. Even more remarkable reduction w/ AA882+febuxostat. Mild to moderate SEs. https://t.co/XrDJXEoC1j

@RheumNow #acr20 abs0600 a case control stdy of 545 CHF exacerbate admissions: pts w/gout flares median LoS 10 d vs 6 d w/out flare or gout at all. log LoS w gout flare 2.41 ± 0.96 vs 1.77 ± 0.90 w/out, p < 0.0001. Prevention of gout flares in CHF pts of essence #ACRbest https://t.co/8xiHHYxvsC